Literature DB >> 10435523

Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics.

F J Wheeler1, D W Nigg, J Capala, P R Watkins, C Vroegindeweij, I Auterinen, T Seppälä, D Bleuel.   

Abstract

The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal-neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well-characterized epithermal-neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR-1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p-Boronophenylaline Fructose (BPA-F) and a hypothetical next-generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal-neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy-tissue tolerance and a reduction in the hydrogen-recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR-1 beam has the better quality (lower hydrogen-recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR-1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435523     DOI: 10.1118/1.598618

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  4 in total

Review 1.  Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors.

Authors:  Thomas E Blue; Jacquelyn C Yanch
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

2.  Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine.

Authors:  Heikki Joensuu; Leena Kankaanranta; Tiina Seppälä; Iiro Auterinen; Merja Kallio; Martti Kulvik; Juha Laakso; Jyrki Vähätalo; Mika Kortesniemi; Petri Kotiluoto; Tom Serén; Johanna Karila; Antti Brander; Eija Järviluoma; Päiivi Ryynänen; Anders Paetau; Inkeri Ruokonen; Heikki Minn; Mikko Tenhunen; Juha Jääskeläinen; Markus Färkkilä; Sauli Savolainen
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

Review 3.  Fission reactor neutron sources for neutron capture therapy--a critical review.

Authors:  Otto K Harling; Kent J Riley
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

4.  Validation and Comparison of the Therapeutic Efficacy of Boron Neutron Capture Therapy Mediated By Boron-Rich Liposomes in Multiple Murine Tumor Models.

Authors:  Charles A Maitz; Aslam A Khan; Peter J Kueffer; John D Brockman; Jonathan Dixson; Satish S Jalisatgi; David W Nigg; Thomas A Everett; M Frederick Hawthorne
Journal:  Transl Oncol       Date:  2017-07-03       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.